Company news

Sarepta Therapeutics, Inc. news in 2025

Sarepta Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 30, 2025

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

December 10, 2025

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

November 24, 2025

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

November 23, 2025

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

November 13, 2025

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

November 2, 2025

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

October 26, 2025

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

October 23, 2025

Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

October 21, 2025

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

October 2, 2025

MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board

September 15, 2025

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

September 4, 2025

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

August 20, 2025

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

August 12, 2025

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

August 5, 2025

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

July 30, 2025

FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy

July 27, 2025

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

July 24, 2025

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

July 24, 2025

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

July 20, 2025

Sarepta Therapeutics Provides Statement on ELEVIDYS

July 17, 2025

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

July 15, 2025

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

June 14, 2025

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

June 3, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

May 20, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

May 15, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

May 15, 2025

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

May 12, 2025

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

May 7, 2025

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

May 5, 2025

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

April 21, 2025

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

April 14, 2025

Sarepta Therapeutics Provides Update on ELEVIDYS

April 3, 2025

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

February 27, 2025

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

February 25, 2025

Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility

February 13, 2025

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results

February 11, 2025

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

January 26, 2025

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

January 12, 2025

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025